Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database.

Ito K, Corrigan B, Romero K, Anziano R, Neville J, Stephenson D, Lalonde R.

J Alzheimers Dis. 2013;37(1):173-83. doi: 10.3233/JAD-130575.

PMID:
23803296
2.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
3.

Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis.

Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, Stephenson D, Gastonguay MR, Corrigan B.

J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):479-98. doi: 10.1007/s10928-012-9263-3. Epub 2012 Jul 21.

PMID:
22821139
4.

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

Irizarry MC, Webb DJ, Bains C, Barrett SJ, Lai RY, Laroche JP, Hosford D, Maher-Edwards G, Weil JG.

J Alzheimers Dis. 2008 Jul;14(3):301-11.

PMID:
18599956
5.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2003;(1):CD000442. Review.

PMID:
12535396
6.

Metrifonate for Alzheimer's disease.

López-Arrieta JM, Schneider L.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003155. Review.

PMID:
16625573
8.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
9.

The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.

Doraiswamy PM, Kaiser L, Bieber F, Garman RL.

Alzheimer Dis Assoc Disord. 2001 Oct-Dec;15(4):174-83. Erratum in: Alzheimer Dis Assoc Disord 2002 Jan-Mar;16(1):48.

PMID:
11723368
10.

Rivastigmine for Alzheimer's disease.

Birks J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(2):CD001191. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001191.

PMID:
10796621
11.

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S.

Dement Geriatr Cogn Disord. 2003;15(2):79-87.

PMID:
12566596
12.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(1):CD001747. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD001747.

PMID:
11279727
13.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
14.

Donepezil for mild and moderate Alzheimer's disease.

Birks J S, Melzer D.

Cochrane Database Syst Rev. 2000;(2):CD001190. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001190.

PMID:
10796620
15.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
17.

A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.

Zhang RY, Leon AC, Chuang-Stein C, Romano SJ.

Clin Trials. 2011 Feb;8(1):5-14. doi: 10.1177/1740774510392255.

PMID:
21335586
18.

Quantification of disease progression and dropout for Alzheimer's disease.

William-Faltaos D, Chen Y, Wang Y, Gobburu J, Zhu H.

Int J Clin Pharmacol Ther. 2013 Feb;51(2):120-31. doi: 10.5414/CP201787.

PMID:
23211395
19.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

Supplemental Content

Support Center